

Confalonieri Paolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1451726/publications.pdf>

Version: 2024-02-01

111
papers

3,666
citations

126858

33
h-index

149623

56
g-index

118
all docs

118
docs citations

118
times ranked

4184
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine.. Journal of Clinical Investigation, 1995, 96, 1137-1144. | 3.9 | 259 |
| 2 | Myasthenia Gravis (MG): Epidemiological Data and Prognostic Factors. Annals of the New York Academy of Sciences, 2003, 998, 413-423. | 1.8 | 135 |
| 3 | Novel mutations of ND genes in complex I deficiency associated with mitochondrial encephalopathy. Brain, 2007, 130, 1894-1904. | 3.7 | 131 |
| 4 | Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. Journal of Neuroimmunology, 2003, 142, 130-136. | 1.1 | 126 |
| 5 | Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. Journal of the Neurological Sciences, 2003, 212, 31-36. | 0.3 | 126 |
| 6 | Transforming growth factor- β 1 and fibrosis in congenital muscular dystrophies. Neuromuscular Disorders, 1999, 9, 28-33. | 0.3 | 122 |
| 7 | Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: Implications for antifibrotic therapy. Journal of Neuroimmunology, 2006, 175, 77-86. | 1.1 | 114 |
| 8 | A Multidisciplinary Evaluation of the Effectiveness of Cyclosporine A in Dystrophic Mdx Mice. American Journal of Pathology, 2005, 166, 477-489. | 1.9 | 107 |
| 9 | Long-term selective IgG immunoadsorption improves Rasmussen's encephalitis. Neurology, 1998, 51, 302-305. | 1.5 | 106 |
| 10 | Factors related to difficulties with employment in patients with multiple sclerosis. International Journal of Rehabilitation Research, 2013, 36, 105-111. | 0.7 | 106 |
| 11 | Anxiety and depression in multiple sclerosis patients around diagnosis. Journal of the Neurological Sciences, 2011, 307, 86-91. | 0.3 | 105 |
| 12 | Increased Expression of β -Chemokines in Muscle of Patients with Inflammatory Myopathies. Journal of Neuropathology and Experimental Neurology, 2000, 59, 164-169. | 0.9 | 81 |
| 13 | Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. Journal of Applied Physiology, 2009, 106, 1311-1324. | 1.2 | 76 |
| 14 | Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology, 2011, 76, 2079-2088. | 1.5 | 71 |
| 15 | Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. PLoS ONE, 2014, 9, e109679. | 1.1 | 67 |
| 16 | Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis. JAMA Neurology, 2018, 75, 35. | 4.5 | 65 |
| 17 | A short plasma exchange protocol is effective in severe myasthenia gravis. Journal of Neurology, 1991, 238, 103-107. | 1.8 | 64 |
| 18 | An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Multiple Sclerosis Journal, 2010, 16, 1393-1405. | 1.4 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Transforming Growth Factor- β 1 in Polymyositis and Dermatomyositis Correlates with Fibrosis but not with Mononuclear Cell Infiltrate. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 479-484. | 0.9 | 57 |
| 20 | Complete stable remission and autoantibody specificity in myasthenia gravis. <i>Neurology</i> , 2013, 80, 188-195. | 1.5 | 53 |
| 21 | Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. <i>Journal of Neurology</i> , 1997, 244, 277-287. | 1.8 | 52 |
| 22 | Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. <i>Neuromuscular Disorders</i> , 2002, 12, 828-835. | 0.3 | 51 |
| 23 | Role of tumour necrosis factor α , but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 344-359. | 1.8 | 51 |
| 24 | Web Search Behavior and Information Needs of People With Multiple Sclerosis: Focus Group Study and Analysis of Online Postings. <i>Interactive Journal of Medical Research</i> , 2014, 3, e12. | 0.6 | 51 |
| 25 | The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. <i>Multiple Sclerosis Journal</i> , 2010, 16, 100-111. | 1.4 | 50 |
| 26 | The relationship between health, disability and quality of life in Myasthenia Gravis: results from an Italian study. <i>Journal of Neurology</i> , 2010, 257, 98-102. | 1.8 | 48 |
| 27 | Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis. <i>Neurological Sciences</i> , 2010, 31, 41-45. | 0.9 | 45 |
| 28 | Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments. <i>PLoS ONE</i> , 2013, 8, e60721. | 1.1 | 44 |
| 29 | First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant. <i>Neuromuscular Disorders</i> , 2006, 16, 237-248. | 0.3 | 41 |
| 30 | Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: Beneficial effect of pentoxifylline. <i>Neurobiology of Disease</i> , 2006, 24, 466-474. | 2.1 | 40 |
| 31 | Impact of natural menopause on multiple sclerosis: a multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1201-1206. | 0.9 | 39 |
| 32 | A resilience group training program for people with multiple sclerosis: Results of a pilot single-blind randomized controlled trial and nested qualitative study. <i>PLoS ONE</i> , 2020, 15, e0231380. | 1.1 | 38 |
| 33 | Anti-titin and Antiryanodine Receptor Antibodies in Myasthenia Gravis Patients with Thymoma. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 538-541. | 1.8 | 35 |
| 34 | Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 663-674. | 1.4 | 35 |
| 35 | A novel mutation (8342G \rightarrow A) in the mitochondrial tRNA ^{Lys} gene associated with progressive external ophthalmoplegia and myoclonus. <i>Neuromuscular Disorders</i> , 1999, 9, 66-71. | 0.3 | 32 |
| 36 | Quantitative Detection of Epstein-Barr Virus DNA in Cerebrospinal Fluid and Blood Samples of Patients with Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e94497. | 1.1 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations. PLoS ONE, 2015, 10, e0127734. | 1.1 | 31 |
| 38 | Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS ONE, 2016, 11, e0153466. | 1.1 | 31 |
| 39 | Allergy and multiple sclerosis: a population-based case-control study. Multiple Sclerosis Journal, 2009, 15, 899-906. | 1.4 | 29 |
| 40 | Immunosuppressive Treatments: Their Efficacy on Myasthenia Gravis Patients' Outcome and on the Natural Course of the Disease. Annals of the New York Academy of Sciences, 1993, 681, 594-602. | 1.8 | 28 |
| 41 | Video-assisted Thoracoscopic Extended Thymectomy (VATET) in Myasthenia Gravis Two-Year Follow-up in 101 Patients and Comparison with the Transsternal Approach. Annals of the New York Academy of Sciences, 1998, 841, 749-752. | 1.8 | 28 |
| 42 | Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials, 2015, 16, 184. | 0.7 | 28 |
| 43 | Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. Multiple Sclerosis Journal, 2010, 16, 1237-1247. | 1.4 | 27 |
| 44 | Difficulties in adjustment to multiple sclerosis: vulnerability and unpredictability of illness in the foreground. Disability and Rehabilitation, 2017, 39, 897-903. | 0.9 | 27 |
| 45 | Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. Neuromuscular Disorders, 2008, 18, 678-680. | 0.3 | 26 |
| 46 | Human Neurotrophin Receptor p75NTR Defines Differentiation-Oriented Skeletal Muscle Precursor Cells: Implications for Muscle Regeneration. Journal of Neuropathology and Experimental Neurology, 2011, 70, 133-142. | 0.9 | 26 |
| 47 | Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. Journal of the Neurological Sciences, 2016, 366, 139-145. | 0.3 | 26 |
| 48 | Identification of a Novel HLA Class II Association with DQB1*0502 in an Italian Myasthenic Population. Annals of the New York Academy of Sciences, 1998, 841, 355-359. | 1.8 | 24 |
| 49 | Protein-A immunoadsorption in immunosuppression-resistant myasthenia gravis. Lancet, The, 1994, 343, 124. | 6.3 | 22 |
| 50 | The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by pro-inflammatory cytokines: relevance for the pathogenesis of inflammatory myopathy. Journal of Neuroimmunology, 1998, 85, 52-58. | 1.1 | 22 |
| 51 | Identification of three novel mutations in the major human skeletal muscle chloride channel gene (CLCN1), causing myotonia congenita. Human Mutation, 1999, 14, 447-447. | 1.1 | 21 |
| 52 | Identification of international classification of functioning, disability and health relevant categories to describe functioning and disability of patients with myasthenia gravis. Disability and Rehabilitation, 2009, 31, 2041-2046. | 0.9 | 21 |
| 53 | A New Thiopurine Sâ€Methyltransferase Haplotype Associated With Intolerance to Azathioprine. Journal of Clinical Pharmacology, 2013, 53, 67-74. | 1.0 | 21 |
| 54 | Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916. | 1.1 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Immune activation in myasthenia gravis: Soluble interleukin-2 receptor, interferon- γ and tumor necrosis factor- α levels in patients' serum. <i>Journal of Neuroimmunology</i> , 1993, 48, 33-36. | 1.1 | 20 |
| 56 | The Kinesin Superfamily Motor Protein KIF4 Is Associated With Immune Cell Activation in Idiopathic Inflammatory Myopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 624-632. | 0.9 | 20 |
| 57 | The POEMS syndrome: Report of six cases. <i>Italian Journal of Neurological Sciences</i> , 1994, 15, 353-358. | 0.1 | 19 |
| 58 | Disability and functional profiles of patients with myasthenia gravis measured with ICF classification. <i>International Journal of Rehabilitation Research</i> , 2009, 32, 167-172. | 0.7 | 19 |
| 59 | Local Dynamic Stability of Gait in People With Early Multiple Sclerosis and No-to-Mild Neurological Impairment. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2020, 28, 1389-1396. | 2.7 | 19 |
| 60 | Effects of Venous Angioplasty on Cerebral Lesions in Multiple Sclerosis: Expanded Analysis of the Brave Dreams Double-Blind, Sham-Controlled Randomized Trial. <i>Journal of Endovascular Therapy</i> , 2020, 27, 9-17. | 0.8 | 18 |
| 61 | Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. <i>Neurological Sciences</i> , 2021, 42, 2637-2644. | 0.9 | 18 |
| 62 | Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness. <i>Journal of the Neurological Sciences</i> , 2016, 368, 402-407. | 0.3 | 17 |
| 63 | Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. <i>BMJ Open</i> , 2017, 7, e017254. | 0.8 | 16 |
| 64 | Development and assessment of a website presenting evidence-based information for people with multiple sclerosis: the IN-DEEP project. <i>BMC Neurology</i> , 2016, 16, 30. | 0.8 | 15 |
| 65 | Excessive fragmentary hypnic myoclonus in a patient affected by a mitochondrial encephalomyopathy. <i>Sleep Medicine</i> , 2006, 7, 663. | 0.8 | 14 |
| 66 | Implementation of the "Sapere Migliora"™ information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1234-1243. | 1.4 | 14 |
| 67 | The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 340. | 1.2 | 14 |
| 68 | Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS trial. <i>Health Expectations</i> , 2014, 17, 36-48. | 1.1 | 12 |
| 69 | Development and validation of the multiple sclerosis questionnaire for the evaluation of job difficulties (MSQ-Job). <i>Acta Neurologica Scandinavica</i> , 2015, 132, 226-234. | 1.0 | 12 |
| 70 | Letter to the editor. <i>Journal of the Neurological Sciences</i> , 2004, 217, 233-234. | 0.3 | 11 |
| 71 | A cloud-based platform for effective supervision of autonomous home rehabilitation through exer-games. , 2018, , . | | 11 |
| 72 | eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. <i>Multiple Sclerosis Journal</i> , 2019, 25, 856-866. | 1.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups. <i>Frontiers in Immunology</i> , 2021, 12, 633167. | 2.2 | 11 |
| 74 | Instrumentally assessed gait quality is more relevant than gait endurance and velocity to explain patient-reported walking ability in early-stage multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2259-2268. | 1.7 | 11 |
| 75 | Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2022, 65, 101491. | 1.1 | 11 |
| 76 | Changes in peripheral blood lymphocyte subset frequencies in myasthenia gravis patients are related to immunosuppression. <i>Journal of Neurology</i> , 1994, 241, 218-222. | 1.8 | 10 |
| 77 | Plasma Treatment in Diseases of the Neuromuscular Junction. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 803-810. | 1.8 | 10 |
| 78 | Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. <i>Journal of Neuroimmunology</i> , 2013, 262, 19-26. | 1.1 | 10 |
| 79 | Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. <i>Quality of Life Research</i> , 2016, 25, 2755-2763. | 1.5 | 10 |
| 80 | Expression of Transforming Growth Factor- β 1 in Thymus of Myasthenia Gravis Patients. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 278-283. | 1.8 | 9 |
| 81 | A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. <i>Neurological Sciences</i> , 2005, 26, s171-s173. | 0.9 | 9 |
| 82 | Immunotherapy responsive startle with antibodies to voltage gated potassium channels. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1281-1290. | 0.9 | 9 |
| 83 | Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. <i>Clinical Immunology</i> , 2016, 173, 133-146. | 1.4 | 9 |
| 84 | Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0200532. | 1.1 | 9 |
| 85 | Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919. | 2.1 | 9 |
| 86 | Antineuronal Antibody in a Patient with Neuroblastoma and Opsoclonus-Myoclonus-Ataxia: A Case Report. <i>Tumori</i> , 1997, 83, 709-711. | 0.6 | 8 |
| 87 | Psychosocial difficulties of individuals with multiple sclerosis: the PARADISE-24 questionnaire. <i>International Journal of Rehabilitation Research</i> , 2016, 39, 339-345. | 0.7 | 8 |
| 88 | Cognitive function alone is a poor predictor of health-related quality of life in employed patients with MS: results from a cross-sectional study. <i>Clinical Neuropsychologist</i> , 2016, 30, 201-215. | 1.5 | 7 |
| 89 | Older age, higher perceived disability and depressive symptoms predict the amount and severity of work-related difficulties in persons with multiple sclerosis. <i>Disability and Rehabilitation</i> , 2019, 41, 2255-2263. | 0.9 | 6 |
| 90 | Assessing balance in non-disabled subjects with multiple sclerosis: Validation of the Fullerton Advanced Balance Scale. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102085. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study. <i>Journal of the Neurological Sciences</i> , 2016, 364, 105-109. | 0.3 | 5 |
| 92 | Walking With Horizontal Head Turns Is Impaired in Persons With Early-Stage Multiple Sclerosis Showing Normal Locomotion. <i>Frontiers in Neurology</i> , 2021, 12, 821640. | 1.1 | 5 |
| 93 | Physical activity in non-disabled people with early multiple sclerosis: A multicenter cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103941. | 0.9 | 5 |
| 94 | Response to Dr. Jaretzki's letter on video-assisted thoracoscopic extended thymectomy. <i>Journal of the Neurological Sciences</i> , 2004, 217, 235-236. | 0.3 | 4 |
| 95 | Assessing measurement invariance of MSQOL-54 across Italian and English versions. <i>Quality of Life Research</i> , 2020, 29, 783-791. | 1.5 | 4 |
| 96 | Emerging Treatments in Myopathies. <i>European Neurology</i> , 1997, 38, 222-229. | 0.6 | 3 |
| 97 | Immunotherapy responsive startle with antibodies to voltage gated potassium channels. <i>BMJ Case Reports</i> , 2009, 2009, bcr0920080988-bcr0920080988. | 0.2 | 3 |
| 98 | A group resilience training program for people with multiple sclerosis: Study protocol of a multi-centre cluster-randomized controlled trial (multi-READY for MS). <i>PLoS ONE</i> , 2022, 17, e0267245. | 1.1 | 3 |
| 99 | Multiple Sclerosis Questionnaire for Job Difficulties (MSQ-Job): definition of the cut-off score. <i>Neurological Sciences</i> , 2016, 37, 777-780. | 0.9 | 2 |
| 100 | Severe thrombocytopenia during Natalizumab therapy: A case report. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116587. | 0.3 | 2 |
| 101 | Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102756. | 0.9 | 2 |
| 102 | Viability of a MSQOL-54 general health-related quality of life score using bifactor model. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 224. | 1.0 | 2 |
| 103 | Idiopathic Inflammatory Myopathies: A Review of Immunopathological Features and Current Models of Pathogenesis. , 0, , . | | 1 |
| 104 | Development of a shortened version of the MSQOL-54 using factor analysis and item response theory. <i>Journal of the Neurological Sciences</i> , 2015, 357, e318-e319. | 0.3 | 1 |
| 105 | Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40Âmg: Need for Titration?. <i>CNS Drugs</i> , 2018, 32, 653-660. | 2.7 | 1 |
| 106 | The IN-DEEP project â€œIntegrating and Deriving Evidence, Experiences, Preferencesâ€: a web information model on magnetic resonance imaging for people with multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 2421-2431. | 1.8 | 1 |
| 107 | Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsingâ€Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study). <i>Frontiers in Neurology</i> , 2021, 12, 637615. | 1.1 | 1 |
| 108 | G.P.6.08 Comparison of the effects of chronic treatments with drugs targeting different disease-related pathways in dystrophic mdx mice. <i>Neuromuscular Disorders</i> , 2007, 17, 803. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | P.12.4 Great phenotypic variability in two siblings affected by congenital myasthenic syndrome associated with mutations in MUSK. <i>Neuromuscular Disorders</i> , 2013, 23, 806. | 0.3 | 0 |
| 110 | P.21.1 Autophagy as a link between immunity and inflammation in idiopathic inflammatory myopathies. <i>Neuromuscular Disorders</i> , 2013, 23, 843-844. | 0.3 | 0 |
| 111 | Miopatie infiammatorie. , 2009, , 539-546. | | 0 |